Download MendeleySelective inhibitors of the FK506-binding protein 51 by induced fit.
Gaali, S., Kirschner, A., Cuboni, S., Hartmann, J., Kozany, C., Balsevich, G., Namendorf, C., Fernandez-Vizarra, P., Sippel, C., Zannas, A.S., Draenert, R., Binder, E.B., Almeida, O.F., Ruhter, G., Uhr, M., Schmidt, M.V., Touma, C., Bracher, A., Hausch, F.(2015) Nat Chem Biol 11: 33-37
- PubMed: 25436518
- DOI: https://doi.org/10.1038/nchembio.1699
- Primary Citation of Related Structures:
4TW6, 4TW7, 4TW8 - PubMed Abstract:
The FK506-binding protein 51 (FKBP51, encoded by the FKBP5 gene) is an established risk factor for stress-related psychiatric disorders such as major depression. Drug discovery for FKBP51 has been hampered by the inability to pharmacologically differentiate against the structurally similar but functional opposing homolog FKBP52, and all known FKBP ligands are unselective. Here, we report the discovery of the potent and highly selective inhibitors of FKBP51, SAFit1 and SAFit2. This new class of ligands achieves selectivity for FKBP51 by an induced-fit mechanism that is much less favorable for FKBP52. By using these ligands, we demonstrate that selective inhibition of FKBP51 enhances neurite elongation in neuronal cultures and improves neuroendocrine feedback and stress-coping behavior in mice. Our findings provide the structural and functional basis for the development of mechanistically new antidepressants.
Organizational Affiliation:
Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
